Cost analysis of the school-based human papillomavirus vaccination programme in Tshwane Health District, South Africa
Article Sidebar
Main Article Content
Abstract
Background. Cervical cancer is a significant public health concern globally. Persistent infection with high-risk human papillomavirus (HPV) types is the necessary cause of virtually all cervical cancers, although rare HPV-negative cervical cancer cases have been reported. HPV is one of the most common sexually transmitted infections worldwide and is responsible for approximately 90% of all cervical cancer cases globally.
Objectives. To estimate the financial costs and cost per fully vaccinated girl (FVG) of the school-based HPV vaccination programme in Tshwane Health District, South Africa.
Methods. We conducted a cross-sectional cost analysis of the 2019 vaccination campaign using the World Health Organization Cancer Prevention and Control Costing (C4P) tool. The data for the programme were obtained from the District Health Information System and financial records. Costs were categorised by component and converted to USD.
Results. The programme reached 15 734 girls with two doses (71.3% uptake). The total financial cost was ZAR21 127 298 (USD1 458 704). Service delivery (71.8%) and vaccine procurement (27.1%) were the main cost drivers. The cost per FVG was ZAR1 343 (USD92.94).
Conclusion. The Tshwane school-based HPV vaccination programme had a high financial cost per FVG compared with other low- and middle-income countries, largely owing to staffing and procurement costs. Optimising delivery strategies can improve cost-efficiency and sustainability.
Article Details
Issue
Section
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The SAJPH is published under an Attribution-Non Commercial International Creative Commons Attribution (CC-BY-NC 4.0) License. Under this license, authors agree to make articles available to users, without permission or fees, for any lawful, non-commercial purpose. Users may read, copy, or re-use published content as long as the author and original place of publication are properly cited.
How to Cite
References
1. Cutts F. Human papillomavirus and HPV vaccines: A review. Bull World Health Organ 2007;85(9):719-726. https://doi.org/10.2471/blt.06.038414
2. Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 2019;144(8):1941-1953. https://doi.org/10.1002/ijc.31937
3. Mbulawa ZZA, van Schalkwyk C, Hu NC, et al. High human papillomavirus (HPV) prevalence in South African adolescents and young women encourages expanded HPV vaccination campaigns. PLoS ONE 2018;13(1):e0190166. https://doi.org/10.1371/journal. pone.0190166
4. Lacey CJN, Lowndes CM, Shah KV. Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. Vaccine 2006;24(Suppl 3):S35-S41. https://doi. org/10.1016/j.vaccine.2006.06.015
5. Arbyn M, Weiderpass E, Bruni L, et al. Estimates of incidence and mortality of cervical cancer in 2018: A worldwide analysis. Lancet Glob Health 2020;8(2):e191-e203. https://doi. org/10.1016/s2214-109x(19)30482-6
6. De Martel C, Ferlay J, Franceschi S, et al. Global burden of cancers attributable to infections in 2008: A review and synthetic analysis. Lancet Oncol 2012;13(6):607-615. https://doi. org/10.1016/s1470-2045(12)70137-7
7. Stelzle D, Tanaka LF, Lee KK, et al. Estimates of the global burden of cervical cancer associated with HIV. Lancet Glob Health 2021;9(2):e161-e169. https://doi.org/10.1016/ s2214-109x(20)30459-9
8. Shrestha AD, Vedsted P, Kallestrup P, Neupane D. Prevalence and incidence of oral cancer in low- and middle-income countries: A scoping review. Eur J Cancer Care (Engl) 2020;29(2):e13207. https://doi.org/10.1111/ecc.13207
9. Pink Ribbon Red Ribbon: Leveraging the HIV platform for women’s cancers. PsycEXTRA Dataset. American Psychological Association, 2012. https://doi.org/10.1037/e628452012-382
10. International Agency for Research on Cancer. Global Cancer Observatory: South Africa. GLOBOCAN 2022, v1.1, updated 8 February 2024. https://gco.iarc.who.int/media/ globocan/factsheets/populations/710-south-africa-fact-sheet.pdf (accessed 5 June 2025).
11. Arbyn M, Bryant A, Martin-Hirsch PP, Xu L, Simoens C, Markowitz L. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev 2013, Issue 12. Art. No.: CD009069. https://doi.org/10.1002/14651858. cd009069.pub2
12. Stanley M. Human papillomavirus vaccines. In: Bloom BR, Lambert P-H, eds. The Vaccine Book. 2nd ed. Cambridge, Mass.: Academic Press (Elsevier), 2016:245-263. https://doi. org/10.1016/B978-0-12-802174-3.00013-8
13. Spinner C, Ding L, Bernstein DI, et al. Human papillomavirus vaccine effectiveness and herd protection in young women. Pediatrics 2019;143(2):e20181902. https://doi. org/10.1542/peds.2018-1902
14. Kahn JA, Widdice LE, Ding L, et al. Substantial decline in vaccine-type human papillomavirus (HPV) among vaccinated young women during the first 8 years after HPV vaccine introduction in a community. Clin Infect Dis 2016;63(10):1281-1287. https://doi. org/10.1093/cid/ciw533
15. McClung NM, Gargano JW, Bennett NM, et al. Trends in human papillomavirus vaccine types 16 and 18 in cervical precancers, 2008-2014. Cancer Epidemiol Biomarkers Prev 2019;28(3):602-609. https://doi.org/10.1158/1055-9965.epi-18-0885
16. Ledibane TD, Ledibane NR, Matlala M. Performance of the school-based human papillomavirus vaccine uptake in Tshwane, South Africa. S Afr J Infect Dis 2023;38(1):a492. https://doi.org/10.4102/sajid.v38i1.492
17. Ochalek J, Abbas K, Claxton K, Jit M, Lomas J. Assessing the value of human papillomavirus vaccination in Gavi-eligible low-income and middle-income countries. BMJ Glob Health 2020;5(10):e003006. https://doi.org/10.1136/bmjgh-2020-003006
18. Burger EA, Campos NG, Sy S, Regan C, Kim JJ. Health and economic benefits of single- dose HPV vaccination in a Gavi-eligible country. Vaccine 2018;36(32):4823-4829. https:// doi.org/10.1016/j.vaccine.2018.04.061
19. Paul P, Fabio A. Literature review of HPV vaccine delivery strategies: Considerations for school- and non-school-based immunisation program. Vaccine 2014;32(3):320-326. https://doi.org/10.1016/j.vaccine.2013.11.070
20. Alonso S, Cambaco O, Maússe Y, et al. Costs associated with delivering HPV vaccination in the context of the first year demonstration programme in southern Mozambique. BMC Public Health 2019;19(1):1031. https://doi.org/10.1186/s12889-019-7338-4
21. Hidle A, Gwati G, Abimbola T, et al. Cost of a human papillomavirus vaccination project, Zimbabwe. Bull World Health Organ 2018;96(12):834-842. https://doi.org/10.2471/ blt.18.211904
22. BotwrightS,HolroydT,NandaS,etal.ExperiencesofoperationalcostsofHPVvaccinedelivery strategies in Gavi-supported demonstration projects. PLoS ONE 2017;12(10):e0182663. https://doi.org/10.1371/journal.pone.0182663
23. Jit M, Brisson M, Portnoy A, Hutubessy R. Cost-effectiveness of female human papillomavirus vaccination in 179 countries: A PRIME modelling study. Lancet Glob Health 2014;2(7):e406-e414. https://doi.org/10.1016/s2214-109x(14)70237-2